LENZ Therapeutics, Inc.
LENZ · XNASCIK 1815776fmd_19ST5GW4CGXW9T59QZCMG6T2NDManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 26 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 0 | 19 |
| Cost of revenue | – | – | – | – | 0 | 0 |
| Gross profit | – | – | – | – | 0 | 19 |
| Realized investment gains (losses) | – | – | – | – | 1 | (0) |
| Research and development | 9 | 38 | 73 | 60 | 30 | 19 |
| Selling, general and administrative | – | – | – | 13 | 29 | 91 |
| Total operating expenses | 14 | 60 | 106 | 72 | 59 | – |
| Operating income | (14) | (60) | (106) | (72) | (59) | (91) |
| Interest and investment income | – | – | – | 2 | 9 | 10 |
| Other non-operating income (expense) | (55) | (10) | 5 | 2 | 9 | 10 |
| Income before taxes | – | – | – | (70) | (50) | (82) |
| Income tax expense | 0 | 0 | 0 | (0) | 0 | 1 |
| Net income from continuing operations | – | – | – | (70) | (50) | (82) |
| Net income | (68) | (71) | (101) | (70) | (50) | (82) |